Current Atherosclerosis Reports

, Volume 12, Issue 1, pp 48–57

Management of the Patient with Statin Intolerance

Article

Abstract

Current guidelines recommend statins as first-line therapy for reducing low-density lipoprotein cholesterol (LDL-C) and preventing cardiovascular events. Patients taking statins frequently experience adverse effects during therapy. The first step is to determine whether the adverse effects are indeed related to statin therapy by statin dechallenge and rechallenge. Strategies for managing statin intolerance include changing statins, intermittent dosing, intensification of lifestyle modifications, and using other LDL-C-lowering agents such as ezetimibe, bile acid sequestrants, and LDL apheresis in suitable patients. More controversial approaches include red yeast rice, coenzyme Q10, and vitamin D supplementation. New therapies for LDL-C lowering are in development.

Keywords

Statin Myalgia Myopathy Hepatotoxicity 

References

Papers of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. 1.
    Grundy SM, Cleeman JI, Merz CNB, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.CrossRefPubMedGoogle Scholar
  2. 2.
    Armitage J: The safety of statins in clinical practice. Lancet 2007, 370:1781–1790.CrossRefPubMedGoogle Scholar
  3. 3.
    Davidson M, Robinson JG: Safety of aggressive lipid management. J Am Coll Cardiol 2007,49:1753–1762.CrossRefPubMedGoogle Scholar
  4. 4.
    Thompson PD, Clarkson PM, Rosenson RS: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:S69–S76.CrossRefGoogle Scholar
  5. 5.
    Law M, Rudnicka AR: Statin safety: a systematic review. Am J Cardiol 2006, 97:S52–S60.CrossRefGoogle Scholar
  6. 6.
    Jacobson TA: Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proceed 2008, 83:687–700.CrossRefGoogle Scholar
  7. 7.
    Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.CrossRefPubMedGoogle Scholar
  8. 8.
    Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007, 50:409–418.CrossRefPubMedGoogle Scholar
  9. 9.
    AstraZeneca Pharmaceuticals: Crestor (rosuvstatin calcium) [prescribing information]. Wilmington, DE, 2009.Google Scholar
  10. 10.
    Cohen D, Anania F, Chalasani N: An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:S77–S81.CrossRefGoogle Scholar
  11. 11.
    Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858–868.PubMedGoogle Scholar
  12. 12.
    • Venero CV, Thompson PD: Managing statin myopathy. Endocrinol Metab Clin N Am 2009, 38:121–136. This is an important review of mechanisms and management strategies for muscle adverse effects associated with statin use.CrossRefGoogle Scholar
  13. 13.
    • Vladutiu GD: Genetic predisposition to statin myopathy. Curr Opin Rheumatol 2008, 20:648–655. This is an important review of genetic risk factors associated with statin-induced myopathy.CrossRefPubMedGoogle Scholar
  14. 14.
    Vladutiu GD, Isackson PJ: SLCO1B1 variants and statin-induced myopathy. N Engl J Med 2009, 360:304.CrossRefPubMedGoogle Scholar
  15. 15.
    Vaklavas C, Chatzizisis YS, Ziakas A, et al.: Molecular basis of statin-associated myopathy. Atherosclerosis 2009, 202:18–28.CrossRefPubMedGoogle Scholar
  16. 16.
    Sathasivam S, Lecky B: Statin induced myopathy. BMJ 2008, 337:1159–1162.CrossRefGoogle Scholar
  17. 17.
    Glueck CJ, Rawal B, Khan NA, et al.: Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009, 58:233–238.CrossRefPubMedGoogle Scholar
  18. 18.
    Bosch X, Poch E, Grau JM: Rhabdomyolysis and acute kidney injury. N Engl J Med 2009, 361:62–72.CrossRefPubMedGoogle Scholar
  19. 19.
    • Onofrei M, Butler K, Fuke D, Miller H: Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008, 28:522–529. This is an important review regarding the safety of statins in patients with preexisting liver disease.CrossRefPubMedGoogle Scholar
  20. 20.
    Stein EA, Ballantyne CM, Windler E, et al.: Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008, 101:490–496.CrossRefPubMedGoogle Scholar
  21. 21.
    Ruisinger JF, Backes JM, Gibson CA, Moriarty PM: Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009, 103:393–394.CrossRefPubMedGoogle Scholar
  22. 22.
    Gadarla M, Kearns AK, Thompson PD: Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol 2008, 101:1747–1748.CrossRefPubMedGoogle Scholar
  23. 23.
    Athyros VG, Tziomalos K, Kakafika AI, et al.: Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008, 101:483–485.CrossRefPubMedGoogle Scholar
  24. 24.
    National Cholesterol Education Panel: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002, 106:3143–3421.Google Scholar
  25. 25.
    Jenkins DJ, Wong JM, Kendall CW, et al.: The effect of a plant-based low-carbohydrate (“Eco-Atkins”) diet on body weight and blood lipid concentrations in hyperlipidemic subjects. Arch Intern Med 2009, 169:1046–1054.CrossRefPubMedGoogle Scholar
  26. 26.
    Weingärtner O, Lütjohann D, Ji S, et al.: Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol 2008, 51:1553–1561.CrossRefPubMedGoogle Scholar
  27. 27.
    Sacks FM, Lichtenstein A, Van Horn L, et al.: Soy protein, isoflavones, and cardiovascular health: A summary of a statement for professionals from the American Heart Association Nutrition Committee. Arterioscler Thromb Vasc Biol 2006, 26:1689–1692.CrossRefPubMedGoogle Scholar
  28. 28.
    Garcia-Calvo M, Lisnock J, Bull HG, et al.: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005, 102:8132–8137.CrossRefPubMedGoogle Scholar
  29. 29.
    Robinson J, Davidson M: Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 2006, 4:461–476.CrossRefPubMedGoogle Scholar
  30. 30.
    Jacobson TA, Armani A, McKenney JM, Guyton JR: Safety considerations with gastrointestinally active lipid-lowering drugs. Am J Cardiol 2007, 99:S47–S55.CrossRefGoogle Scholar
  31. 31.
    Kastelein JJ, Akdim F, Stroes ES, et al: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008, 358:1431–1443.CrossRefPubMedGoogle Scholar
  32. 32.
    Robinson JG, Davidson M: Is it over for ezetimibe? Exp Rev Cardiovasc Ther 2008, 6:781–783.CrossRefGoogle Scholar
  33. 33.
    Rossebo AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359:1343–1356.CrossRefPubMedGoogle Scholar
  34. 34.
    Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359:1357–1366.CrossRefPubMedGoogle Scholar
  35. 35.
    Cholesterol Treatment Trialists’ (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.CrossRefGoogle Scholar
  36. 36.
    Fleg JL, Mete M, Howard BV, et al.: Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008, 52:2198–2205.CrossRefPubMedGoogle Scholar
  37. 37.
    Bays H, Goldberg R. The ‘forgotten’ bile acid sequestrants: is now a good time to remember? Am J Ther 2007, 14:567–580.CrossRefPubMedGoogle Scholar
  38. 38.
    Bays HE, Davidson M, Jones MR, Abby SL: Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006, 97:1198–1205.CrossRefPubMedGoogle Scholar
  39. 39.
    Bays HE, Goldberg RB, Truitt KE, Jones MR: Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008, 168:1975–1983.CrossRefPubMedGoogle Scholar
  40. 40.
    Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46:1855–1862.CrossRefPubMedGoogle Scholar
  41. 41.
    Knopp RH, Tsunehara C, Retzlaff BM, et al.: Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006, 55:1697–1703.CrossRefPubMedGoogle Scholar
  42. 42.
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185–197.CrossRefPubMedGoogle Scholar
  43. 43.
    Becker DJ, Gordon RY, Halbert SC, et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830–839.PubMedGoogle Scholar
  44. 44.
    Becker DJ, Gordon RY, Morris PB, et al.: Simvastatin vs therapeutic lifestyle changes and supplements: Randomized primary prevention trial. Mayo Clin Proceed 2008, 83:758–764.CrossRefGoogle Scholar
  45. 45.
    Lu Z, Kou W, Du B, et al.: Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008, 101:1689–1693.CrossRefPubMedGoogle Scholar
  46. 46.
    Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007, 49:2231–2237.CrossRefPubMedGoogle Scholar
  47. 47.
    Lee JH, O’Keefe JH, Bell D, et al.: Vitamin D deficiency: an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008, 52:1949–1956.CrossRefPubMedGoogle Scholar
  48. 48.
    Thompson GR: Recommendations for the use of LDL apheresis. Atherosclerosis 2008, 198:247–255.CrossRefPubMedGoogle Scholar
  49. 49.
    Stein EA: Other therapies for reducing low-density lipoprotein cholesterol: medications in development. Endocrinol Metab Clin North Am 2009, 38:99–119.CrossRefPubMedGoogle Scholar
  50. 50.
    Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354: 1264–1272.Google Scholar
  51. 51.
    Bloomfield D, Carlson GL, Sapre A, et al.: Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009, 157:352.e2–360.e2.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of Iowa Hospitals and ClinicsIowa CityUSA
  2. 2.Departments of Epidemiology & Medicine, Director, Lipid Research ClinicUniversity of IowaIowaUSA

Personalised recommendations